Evolus, Inc. (EOLS)
NASDAQ: EOLS · Real-Time Price · USD
6.79
+0.10 (1.49%)
At close: Oct 21, 2025, 4:00 PM EDT
6.79
0.00 (0.00%)
After-hours: Oct 21, 2025, 4:10 PM EDT
Evolus Revenue
Evolus had revenue of $69.39M in the quarter ending June 30, 2025, with 3.70% growth. This brings the company's revenue in the last twelve months to $277.94M, up 17.15% year-over-year. In the year 2024, Evolus had annual revenue of $266.27M with 31.76% growth.
Revenue (ttm)
$277.94M
Revenue Growth
+17.15%
P/S Ratio
1.53
Revenue / Employee
$837,172
Employees
332
Market Cap
439.21M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 266.27M | 64.19M | 31.76% |
| Dec 31, 2023 | 202.09M | 53.47M | 35.98% |
| Dec 31, 2022 | 148.62M | 48.94M | 49.10% |
| Dec 31, 2021 | 99.67M | 43.13M | 76.29% |
| Dec 31, 2020 | 56.54M | 21.62M | 61.89% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
EOLS News
- 11 days ago - Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler Launch - PRNewsWire
- 5 weeks ago - Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer - Business Wire
- 2 months ago - Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp - Business Wire
- 2 months ago - Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product - Business Wire
- 2 months ago - Evolus, Inc. (EOLS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates - Business Wire